MRNS $5.55 Bought a full position yesterday at $5.55
Link back for upcoming catalyst news. From their May PR:
The Company is on-track to report top-line data in the upcoming weeks from the Phase 2 proof-of-concept, investigator-sponsored clinical study in patients with Fragile X syndrome. The study incorporates several clinician- and parental-validated scales to evaluate the effect of ganaxolone on anxiety, attention, social behavior, aggression, hyperactivity, and language.
The Company is on-track to report top-line data in the middle of 2016 from the Phase 3 clinical trial evaluating ganaxolone in adults with focal onset seizures.
The Company is on-track to report top-line data in the middle of 2016 from the Phase 2, proof-of-concept clinical trial evaluating ganaxolone in pediatrics with PCDH19.
At March 31, 2016, the Company had cash, cash equivalents and investments of $51.4 million, compared to $57.7 million at December 31, 2015. The Company believes that its cash, cash equivalents and investments, as of March 31, 2016, are adequate to fund operations into the second half of 2017.